Inmune Bio, Inc.
Close on Oct 19, 2026
- Market cap
- $41.15M
- P/E (TTM)
- –
- Dividend yield
- –
About Inmune Bio
Biological Products, (No Diagnostic Substances), SIC 2836
INmune Bio Inc. is a clinical-stage biotechnology company focused on developing therapies that reprogram the innate immune system to treat diseases driven by chronic inflammation and immune dysfunction. Its clinical pipeline includes CORDStrom, an allogeneic, human umbilical cord-derived mesenchymal stromal cell therapy for recessive dystrophic epidermolysis bullosa; XPro1595, a biologic targeting neuroinflammation in early Alzheimer’s disease by neutralizing soluble tumor necrosis factor; and INKmune, a natural killer cell-priming therapeutic platform evaluated for hematologic malignancies and metastatic castrate-resistant prostate cancer. The company's therapies are designed for patients suffering from severe inflammatory conditions, neurodegenerative disorders, and oncology indications.
The company operates internationally across several clinical and manufacturing jurisdictions. It conducts research, development, and clinical trials across sites in the United States, the United Kingdom, Australia, Canada, and European countries including France, Germany, Spain, the Czech Republic, and Slovakia. Additionally, cellular manufacturing for CORDStrom is located in the United Kingdom. INmune Bio maintains its principal executive offices in Boca Raton, Florida.
Summary of the business section of Inmune Bio's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Inmune Bio, Inc.
- Headquarters
- Boca Raton, FL
- Address
- 225 Ne Mizner Blvd, Suite 640 33432
- Phone
- (858) 964-3720
- Employees
- 6, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Nevada
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C., Houston, Texas
Stock & identifiers
- Ticker
- INMB
- Exchange
- Nasdaq
- Shares outstanding
- 28M, Aug 6, 2026
- Public float
- $51.00M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company
- SEC CIK
- 1711754
- CUSIP
- 45782T105
- ISIN
- US45782T1051
- EIN
- 47-5205835
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| David J. Moss | Chief Executive Officer, Director | 1,294,883 |
| Raymond Joseph Tesi | President and CEO, Director | 1,554,106 |
| Mark William Lowdell | Chief Scientific Officer | 1,518,017 |
| Cory Randall Ellspermann | CFO | – |
| Ronnie Duane Clark | Director | – |
| James Sapirstein | Director | – |
| Scott Juda | Director | 158,007 |
| Marcia Allen | Director | – |
| Timothy j. Schroeder | Director | 82,187 |
| James Kelly Ganjei | Director | 17,793 |
CEO pay and shareholder return
Pay versus performance table from the proxy statement
| Fiscal year | CEO total pay | CEO pay actually paid | Other executives (avg) | Value of $100 invested | Peer group |
|---|---|---|---|---|---|
| FY2025 David Moss | $1.85M | $1.28M | $1.04M | $-67 | – |
| FY2025 RJTesi | $2.85M | $1.40M | $1.04M | $-67 | – |
| FY2024 RJTesi | $3.01M | $1.94M | $2.26M | $-59 | – |
| FY2024 Raymond J. | $3.01M | $1.94M | $2.26M | $-59 | – |
| FY2023 RJTesi | $1.69M | $2.52M | $869.73K | $78 | – |
| FY2023 Raymond J. | $1.69M | $2.52M | $869.73K | $78 | – |
“Actually paid” adjusts reported pay for changes in the value of equity awards. Shareholder return assumes $100 invested at the start of the measurement period, as disclosed by the company.
Employees
Headcount reported in annual reports
“had 6 full-time employees in the United States and 15 full-time employees in the United Kingdom.”
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| May 7, 2025 | Auditor change | Change in certifying accountant (8-K Item 4.01) |
| Dec 30, 2020 | Listing | Registration of securities on an exchange (Form 8-A) |
| Jun 4, 2019 | Listing notice | Notice of delisting or failure to satisfy a listing rule (8-K Item 3.01) |
| Feb 1, 2019 | Listing | Registration of securities on an exchange (Form 8-A) |